Skip to main content

📊 In a 40-yr cohort (n=2818), RA pts had 2.3x ↑ risk of DVT (HR 2.26) & 1.6x ↑ risk of PE (HR 1.61) vs non-RA

Social Author Name
Jiha Lee
Tweet Content
📊 In a 40-yr cohort (n=2818), RA pts had 2.3x ↑ risk of DVT (HR 2.26) & 1.6x ↑ risk of PE (HR 1.61) vs non-RA. Risk ↑ with RF/CCP+, nodules (HR 2.9), BMI ≥30 (HR 1.9), & biologic use in year 1 (HR 2.4–2.9). Remission = ↓ PE risk (HR 0.47) 📍OP0070 @RheumNow #EULAR2025

POS0627: RA patients aged ≥90 yrs can benefit from biologics/JAKi! In 3,600 pts, 84% of those ≥90 achieved low disea

Social Author Name
Jiha Lee
Tweet Content
POS0627: RA patients aged ≥90 yrs can benefit from biologics/JAKi! In 3,600 pts, 84% of those ≥90 achieved low disease activity, 71% were on JAKi. But serious infections occurred in 21%—mostly pneumonia. Use w/caution in the oldest-old. #EULAR2025 @rheumnow

#Probiotics +#methotrexate giving far more #remission in #rheumatoid #arthritis than #MTX alone? Seems fishy…. oops

Social Author Name
Janet Pope
Tweet Content
#Probiotics +#methotrexate giving far more #remission in #rheumatoid #arthritis than #MTX alone? Seems fishy…. oops - #fish #oil #omega3 #fatty #acids do work! not sure re the huge benefit of ‘immunebiotics’ #EULAR2025 @RheumNow @eular_org abst#POS0483 https://t.co/STQuaOkBcY

Closing the care divide in #JIA treatment plenary session Overall theme in #EULAR2025 is everyone talking about AI and

Social Author Name
Bella Mehta
Tweet Content
Closing the care divide in #JIA treatment plenary session Overall theme in #EULAR2025 is everyone talking about AI and digital health on day 1 Biologics have changed the game! @RheumNow https://t.co/qDqbz8JApe

Data from a German cohort evaluated the frequency of D2M-axSpA using the new D2M definition and showed: > Female pts

Social Author Name
Adela Castro
Tweet Content
Data from a German cohort evaluated the frequency of D2M-axSpA using the new D2M definition and showed: > Female pts > Peripheral SpA symptoms < HLAB27 positive < Education level < Objective signs: MRI-inflammation in the spine or elevated CRP levels. also PROs were worse in
Health inequities in rheumatology: A central theme
This year at EULAR, health inequalities have taken centre stage as fundamental drivers of outcomes in rheumatic and musculoskeletal diseases. Across multiple sessions and studies, delegates are presenting compelling evidence and ground-breaking research demonstrating that who you are, where you live, and what resources you can access truly do shape the trajectory of chronic illness just as much as biological factors.
Difficult-to-Manage AxSpA: Global Prevalence and Associated Factors
The concept of Difficult-to-Manage (D2M) axial spondyloarthritis (axSpA) is a recent development, with the first expert consensus definition published by the Assessment of SpondyloArthritis International Society (ASAS) earlier this year. This unified definition has stimulated a wave of new research globally, with multiple studies analysing D2M axSpA in diverse clinical cohorts.

#EULAR2025 Abstr#OP0077 Which MSK item/tool is important when assessing #SLE arthritis?Cohort study showed: -SJC = good

Social Author Name
Md Yuzaiful Md Yusof
Tweet Content
#EULAR2025 Abstr#OP0077 Which MSK item/tool is important when assessing #SLE arthritis?Cohort study showed: -SJC = good specificity. Correlated with US synovitis but not patient-defined response -New tool, LAMDA correlated with US & patient response. May be used in RCT @RheumNow https://t.co/srVLKw2pcL

❓️How effective and safe is it to combine bDMARDs and tsDMARDS (i.e. TNFi/ IL17i + JAKi/TYKi) in #psoriatic_arthrit

Social Author Name
Nelly ZIADE 🍀
Tweet Content
❓️How effective and safe is it to combine bDMARDs and tsDMARDS (i.e. TNFi/ IL17i + JAKi/TYKi) in #psoriatic_arthritis? 🅰️ Reassuring data from a case-series study presented by Andre Lucas Ribeiro #EULAR2025 OP0090 @RheumNow #Strategy https://t.co/W8fuzSgxbJ
Subscribe to
×